- Active, not recruiting
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
Updated: Oct 24, 2022
LocoMMotion
Relapsed & Refractory Multiple Myeloma
NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
Sponsor
Janssen-Cilag Ltd.
Collaborator
Legend Biotech
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04035226
Official Title: A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
First Posted : July 29, 2019
Click here to see details on ClinicalTrials.gov
Observational Study
No intervention will be administered as a part of this study.
Patients with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The main source of data collection will be medical records of each patient.
- Multiple Locations
- International Study
Leukemia: 2022 Mar 24 - LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Abstract: The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
Click here for details
June 28, 2022
International Myeloma Foundation
Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma
Locations
United States, Arizona
United States, California
United States, Florida
United States, Illinois
United States, Michigan
United States, Missouri
United States, Nevada
United States, New Jersey
United States, New York
United States, Ohio
Europe
United Kingdom
France
Germany
Italy
Spain
Netherlands
Belgium
Poland
Asia
Russian Federation